Showing 50 of 50 results

Charles Mgone, Tom Evans, Uli Fruth
Tom Evans (AERAS), Uli Fruth (WHO)
Nationally representative household survey that provides data for wide range of monitoring and impact evaluation indicators in the areas of population, health and nutrition. ,Nationally...
Chair Mary Marovich
HIV – Kathryn Mngadi (Caprisa/HVTN), Punee Pitisittithum (Mahidol University); TB – Gerald Voss (Global HIV Vaccine Enterprise), Willem Hanekom (BMGF); Malaria – Fred Binka (University of...
Robin Kobbe, Marta Gacic-Dobo, M. Carolina Danovaro-Holliday, Laure B. Dumolard, Jan Grevendonk, Daniel Lüdecke, Cornelius Rau, Brenton M. Wiernik
Analyzing immunization coverage data is crucial to guide decision-making in national immunization programs and monitor global initiatives such as the Immunization Agenda 2030. We aimed to assess the...
Alejandro Cravioto, David Kaslow, Rino Rappuoli, Birgitte Giersing, Deepali Pate, Narendra Arora, Ian Hudson, Joshua Chu, Sai Prasad
0:05 - Opportunities, risks, and potential valleys of death, David Kaslow, PATH. 16:22 - Is there a role for early policy decision? Rino Rappuoli, GSK. 27:58 - Building the concept of Preferred...
Ann Ginsberg
Recent results in TB vaccine R&D are game-changing: what key challenges and opportunities remain?
Birgitte Giersing
Strategic intent for Preferred Policy Profiles and proposed test cases
World Health Organization (WHO)
The WHO initiative, Market Information for Access to Vaccines (MI4A) produces vaccine-specific market studies, analyzing global demand and supply prospects for individual vaccines. The studies...
World Health Organization (WHO)
WHO working document on BCG Vaccine Global Market Update
TaniaCernuschi et al.
Over the past decade, several countries across all regions, income groups and procurement methods have been unable to secure sufficient BCG vaccine supply. While the frequency of stock-outs has...
World Health Organization (WHO)
WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention,...
Marie-ClaudeRousseau et al.
Background: In the province of Québec, Canada, the Bacillus Calmette-Guérin (BCG) vaccine was offered to newborns and school-age children from the 1950s to mid-1970s in an organized tuberculosis...
Nissen TN et al.
INTRODUCTION: BCG vaccination has been associated with beneficial non-specific effects on child health. Some immunological studies have reported heterologous effects of vaccines on antibody responses...
Hennie D. Geldenhuys, Helen Mearns, Jennifer Foster, Eugene Saxon, Benjamin Kagina, Laura Saganic, Courtney Jarrahian, Michele D. Tameris, One B. Dintwe, Michele Van Rooyen, Kany-Kany A. Luabeya, Gregory Hussey, Thomas J. Scriba, Mark Hatherill, Darin Zehrung
Intradermal bacille Calmette-Guérin (BCG) vaccination by needle-free, disposable-syringe jet injectors (DSJI) is an alternative to the Mantoux method using needle and syringe (NS). We compared the...
Rebecca C. Harris et al.
Background The Bacillus Calmette-Guérin (BCG) vaccine is provided to over 100 million neonates annually to protect against childhood tuberculosis (TB). Recent BCG manufacturing interruptions...
Dawit Gebreegziabiher et al.
M. tuberculosis and helminth infection each affects one third of the world population. Helminth infections down regulate cell mediated immune responses and this may contribute to lower efficacy of...
Anjana Roy, Ajit Lalvani, Ibrahim Abubakar, Ifedayo Adetifa, Laura C. Rodrigues, Luke B. Snell, Michael Eisenhut, Punam Mangtani, Ross Harris, Stephanie Habermann, Saranya Sridhar
Objectives To determine whether BCG vaccination protects against Mycobacterium tuberculosis infection as assessed by interferon γ release assays (IGRA) in children. Design Systematic review and...
Fernando Luiz Cunha Castelo Branco et al.
Vaccines are very important to reduce morbidity and mortality by preventable infectious diseases, especially during childhood. Optimal coverage is not always achieved, for several reasons. Here we...
F. Lutwama et al.
Distinct patterns of T-cell induction occurred when BCG vaccine was given at birth and at 6 weeks of age. The authors propose that this diversity might impact protection against tuberculosis. Our...
Tameris MD et al.
BCG vaccination provides incomplete protection against tuberculosis in infants. A new vaccine, modified Vaccinia Ankara virus expressing antigen 85A (MVA85A), was designed to enhance the protective...
Thysen SM et al.
BCG vaccination is recommended at birth in low-income countries, but vaccination is often delayed. Often 20-dose vials of BCG are not opened unless at least ten children are present for vaccination...
Favorov M et al.
Except during a 1-year period when BCG vaccine was not routinely administered, annual coverage of infants with Bacillus Calmette-Guérin (BCG) in Kazakhstan since 2002 has exceeded 95%. BCG...
Yu Pang et al.
Bacille Calmette-Guérin (BCG) vaccine is still the most effective approach to prevent tuberculosis in childhood. In order to provide protection against severe forms of childhood tuberculosis, it is...
Patrick Nguipdop-Djomo et al.
Little is known about how long the BCG vaccine protects against tuberculosis. This study assessed the long-term vaccine effectiveness (VE) in Norwegian-born individuals.
Elma Z. Tchilian et al.
Mice were immunized parenterally, intranasally or simultaneously by both routes with BCG or recombinant mycobacterial antigens plus appropriate adjuvants. They were challenged with Mycobacterium...
Renate A. Richardus et al.
An unexpectedly high proportion of healthy contacts of leprosy patients presented with PB leprosy within 12 weeks after receiving BCG vaccination, possibly as a result of boosted cell-mediated...
Victoria Nankabirwa et al.
Data on non-specific effects of BCG vaccination in well described, general population African cohorts is scanty. The researchers report the effects of BCG vaccination on post-neonatal infant and...
Maria-Jose Iglesias, Carlos Martin
BCG, or Bacille Calmette-Guerin, is a live attenuated vaccine derived fromMycobacterium bovis, originally isolated from cattle. BCG is the only vaccine available for the prevention of human forms of...
Lisbeth Marianne Thøstesen et al.
Studies from low-income countries report positive non-specific effects of early Bacillus Calmette-Guérin (BCG) immunisation on childhood health and survival. Neonatal immunisation with BCG may prime...
Abdelmoneim E.M. Kheir, Samar A. Ibrahim, Abdelmoneim A. Alhaj
Tuberculosis remains a major cause of morbidity and mortality worldwide. Bacille Calmette Guerin (BCG) is the current vaccine for tuberculosis. The absence or presence of a scar is used as an...
Mauricio L. Barreto et al.
BCG revaccination is still used in some tuberculosis endemic countries. Until now, the little evidence available suggested that BCG revaccination confers very limited additional protection, although...
Stefan HE Kaufmann
Tuberculosis is one of the most deadly infectious diseases. The situation is worsening because of co-infection with HIV and increased occurrence of drug resistance. Although the BCG vaccine has been...
Dierig A et al.
The study concludes that immunisation policies regarding BCG vaccine exist in the majority of European countries. Indications for BCG immunisation varied considerably, likely reflecting national TB...
Maeve K. Lalor et al.
BCG vaccination is administered in infancy in most countries with the aim of providing protection against tuberculosis. There is increasing interest in the role of vitamin D in immunity to...
Somsak Thamthitiwat et al.
We describe four cases of Mycobacterium tuberculosis complex bacteremia diagnosed in immunocompetent neonates, who presented with high fevers and/or jaundice within 72 h after Bacille...
Kaufmann SH et al.
Tuberculosis continues to kill 1·4 million people annually. During the past 5 years, an alarming increase in the number of patients with multidrug-resistant tuberculosis and extensively...
Peter Andersen & Joshua S. Woodworth
Highlights: •Protection can be improved by supplementing instead of boosting BCG immune responses. •T cell responses not detectable by IFN-γ assays can enhance TB control. •Improving central...
Channing L & Sinanovic E
Tuberculosis remains the leading cause of death in South Africa. A number of potential new TB vaccine candidates have been identified and are currently in clinical trials. One such candidate is...
Meyer J et al.
New vaccines to prevent tuberculosis are urgently needed. MVA85A is a novel viral vector TB vaccine candidate designed to boost BCG-induced immunity when delivered intradermally. To date,...
Nicole Ritz, Ulrich Heininger, Uros Krivec, Marc Tebruegge, Alexa Dierig
BACKGROUND: The incidence of tuberculosis (TB) and the use of Bacille Calmette-Guérin (BCG) vaccines differ significantly worldwide. Information regarding recent changes in BCG use and immunisation...
Priya Saikumar Lakshmi et al.
The expression of functional Mycobacterium tuberculosis antigens in transplastomic plants should facilitate development of a cost-effective and orally deliverable TB booster vaccine with potential...
Rajpal S Kashyap et al.
Tuberculosis (TB) is one of the most prevalent cause of death due to a single pathogen. Bacillus Calmette Guérin (BCG) is the only vaccine available for clinical use that protects against miliary...
JHSPH
A mathematical modelling tool that estimates the impact of scaling up high-impact MNCH and nutrition interventions in low- and middle-income countries. It estimates the impact of these interventions...
World Health Organization (WHO)
Over the past three years, there has been a decline in global availability of BCG vaccine. At the same time, demand from 70 countries traditionally procuring through one procurement agency, UNICEF...